Compare Snap Inc (SNAP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs Viatris Inc — how do they compare? Snap Inc trades at $4.58 (market cap $7.67B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 2.6× Snap Inc's market cap, and Viatris Inc pays a 2.83% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| SNAP | VTRS | |
|---|---|---|
Market Cap | $7.67B | $19.79B |
Sector | Media | Health |
52-Week High | $10.35 | $17.39 |
52-Week Low | $3.93 | $8.74 |
Enterprise Value | $9.05B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $4.56, up 0.77% on the day, with a bearish technical signal and mixed fundamentals. Revenue grew to $5.93B in 2025, but net losses persist at -$460M. The stock shows improving cash flow from operations and has beaten EPS estimates in recent quarters. Analyst consensus is a 'Hold' with a $5.83 price target, suggesting modest upside from current levels.
The outlook remains cautious due to ongoing losses and competitive pressures, though cost-cutting and AR initiatives offer potential. Key risks include high debt, regulatory scrutiny, and uncertain demand for new products like SPECS glasses. Upside depends on sustained user engagement and profitability improvements.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
